Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers

Behnaz Khavari, Murray J Cairns, Behnaz Khavari, Murray J Cairns

Abstract

Schizophrenia is a severe psychiatric disorder with a complex array of signs and symptoms that causes very significant disability in young people. While schizophrenia has a strong genetic component, with heritability around 80%, there is also a very significant range of environmental exposures and stressors that have been implicated in disease development and neuropathology, such as maternal immune infection, obstetric complications, childhood trauma and cannabis exposure. It is postulated that epigenetic factors, as well as regulatory non-coding RNAs, mediate the effects of these environmental stressors. In this review, we explore the most well-known epigenetic marks, including DNA methylation and histone modification, along with emerging RNA mediators of epigenomic state, including miRNAs and lncRNAs, and discuss their collective potential for involvement in the pathophysiology of schizophrenia implicated through the postmortem analysis of brain tissue. Given that peripheral tissues, such as blood, saliva, and olfactory epithelium have the same genetic composition and are exposed to many of the same environmental exposures, we also examine some studies supporting the application of peripheral tissues for epigenomic biomarker discovery in schizophrenia. Finally, we provide some perspective on how these biomarkers may be utilized to capture a signature of past events that informs future treatment.

Keywords: DNA methylation; Schizophrenia; histone modification; long non-coding RNA; miRNA.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Transcriptional and post-transcriptional regulation of gene expression. The four panels of this schematic are representative of the major epigenomic mechanisms’ associated active and inactive states in the nucleus and cytoplasm. Active chromatin (top left) characterized by an expanded or open euchromatin domain is established by the depletion of histone H3 lysing 27 trimethylation (K27(CH3)3 red) and an increase in histone H3 and H4 acetylation (green). This gives rise to mRNA transcription and non-coding RNA, such as primary miRNA transcripts. After interaction with the microprocessor complex (Drosha/DGCR8), the processed pre-miR are exported to the cytoplasm via exportin 5. mRNA is also exported to the cytoplasm (top right panel) where it becomes associated with ribosomes and translated into protein (blue). This is facilitated by the suppression of potentially active miRNA, which are sequestered through interaction with lincRNA and circRNA. Inactive chromatin (bottom left) is associated with cytosine methylation (red), which is particularly important at CpG islands and promoters where they can bind to MeCP2 which can recruit histone de-acetylases (HDAC). These reduce histone acetylation, which leads to greater compaction of chromatin into a state known as heterochromatin. LincRNA transcripts can also form a scaffold for the assembly of a ribonucleoprotein complex, including the PRC2, that directs the activity of histone methyltransferases (HMTs) that catalyze the trimethylation of histone H3 lysine 27. This modification also further enhances the contraction of chromatin into inactive heterochromatin. Post-transcriptional regulation of gene expression (bottom right panel) can also be facilitated by the maturation of pre-miRs through the activity of dicer. The mature miRNAs guide the RNA-induced silencing complex (comprising Argonaute proteins and other co-factors) to the 3′UTR of their cognate mRNA, causing translational repression and degradation through exonuclease activity.
Figure 2
Figure 2
Putative target gene interaction network graph generated using Ingenuity Pathway Analysis of miR-34 and miR-181 family miRNAs nodes within a simulated cell. Target mRNA interactions are denoted by green and blue edges for the seed sequences GGCAGUG and ACAUUCA using high stringency target predictions (TargetScan) and experimental observation for miR-34 and miR-181, respectively. Protein–protein interactions between miRNA targets are illustrated in pink. Gene ontologies related to neural functions are projected from the right side (grey lines) with the highest number of interactions at the top (axonal guidance signaling) and the least at the bottom (neuregulin signaling).

References

    1. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008;30:67–76. doi: 10.1093/epirev/mxn001.
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2.
    1. Owen M.J., Sawa A., Mortensen P.B. Schizophrenia. Lancet. 2016;388:86–97. doi: 10.1016/S0140-6736(15)01121-6.
    1. Lichtermann D., Karbe E., Maier W. The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2000;250:304–310. doi: 10.1007/s004060070005.
    1. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427. doi: 10.1038/nature13595.
    1. Pardiñas A.F., Holmans P., Pocklington A.J., Escott-Price V., Ripke S., Carrera N., Legge S.E., Bishop S., Cameron D., Hamshere M.L., et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 2018;50:381–389. doi: 10.1038/s41588-018-0059-2.
    1. Marshall C.R., Howrigan D.P., Merico D., Thiruvahindrapuram B., Wu W., Greer D.S., Antaki D., Shetty A., Holmans P.A., Pinto D., et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat. Genet. 2017;49:27–35. doi: 10.1038/ng.3725.
    1. Lewis S.W., Murray R.M. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. J. Psychiatr. Res. 1987;21:413–421. doi: 10.1016/0022-3956(87)90088-4.
    1. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder? Br. Med. J. (Clin. Res. Ed.) 1987;295:681–682. doi: 10.1136/bmj.295.6600.681.
    1. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 1987;44:660–669. doi: 10.1001/archpsyc.1987.01800190080012.
    1. McCullumsmith R.E., Meador-Woodruff J.H. Novel approaches to the study of postmortem brain in psychiatric illness: Old limitations and new challenges. Biol. Psychiatry. 2011;69:127–133. doi: 10.1016/j.biopsych.2010.09.035.
    1. Richetto J., Meyer U. Epigenetic Modifications in Schizophrenia and Related Disorders: Molecular Scars of Environmental Exposures and Source of Phenotypic Variability. Biol. Psychiatry. 2020 doi: 10.1016/j.biopsych.2020.03.008.
    1. Smigielski L., Jagannath V., Rössler W., Walitza S., Grünblatt E. Epigenetic mechanisms in schizophrenia and other psychotic disorders: A systematic review of empirical human findings. Mol. Psychiatry. 2020 doi: 10.1038/s41380-019-0601-3.
    1. Friston K.J., Frith C.D. Schizophrenia: A disconnection syndrome? Clin. Neurosci. 1995;3:89–97.
    1. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: A meta-analysis. Schizophr. Res. 2005;76:1–23. doi: 10.1016/j.schres.2004.12.002.
    1. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 2000;57:65–73. doi: 10.1001/archpsyc.57.1.65.
    1. Stephan K.E., Friston K.J., Frith C.D. Dysconnection in schizophrenia: From abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 2009;35:509–527. doi: 10.1093/schbul/sbn176.
    1. Jang H.S., Shin W.J., Lee J.E., Do J.T. CpG and Non-CpG Methylation in Epigenetic Gene Regulation and Brain Function. Genes (Basel) 2017;8 doi: 10.3390/genes8060148.
    1. Lister R., Mukamel E.A., Nery J.R., Urich M., Puddifoot C.A., Johnson N.D., Lucero J., Huang Y., Dwork A.J., Schultz M.D., et al. Global epigenomic reconfiguration during mammalian brain development. Science. 2013;341:1237905. doi: 10.1126/science.1237905.
    1. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–463. doi: 10.1038/nature02625.
    1. Nabil Fikri R.M., Norlelawati A.T., Nour El-Huda A.R., Hanisah M.N., Kartini A., Norsidah K., Nor Zamzila A. Reelin (RELN) DNA methylation in the peripheral blood of schizophrenia. J. Psychiatr. Res. 2017;88:28–37. doi: 10.1016/j.jpsychires.2016.12.020.
    1. Qureshi I.A., Mehler M.F. Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat. Rev. Neurosci. 2012;13:528–541. doi: 10.1038/nrn3234.
    1. Sharaf A., Rahhal B., Spittau B., Roussa E. Localization of reelin signaling pathway components in murine midbrain and striatum. Cell Tissue Res. 2015;359:393–407. doi: 10.1007/s00441-014-2022-6.
    1. Shifman S., Johannesson M., Bronstein M., Chen S.X., Collier D.A., Craddock N.J., Kendler K.S., Li T., O’Donovan M., O’Neill F.A., et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 2008;4:e28. doi: 10.1371/journal.pgen.0040028.
    1. Wedenoja J., Tuulio-Henriksson A., Suvisaari J., Loukola A., Paunio T., Partonen T., Varilo T., Lönnqvist J., Peltonen L. Replication of association between working memory and Reelin, a potential modifier gene in schizophrenia. Biol. Psychiatry. 2010;67:983–991. doi: 10.1016/j.biopsych.2009.09.026.
    1. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., Uzunov D.P., Smalheiser N.R., Davis J.M., Pandey G.N., et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. USA. 1998;95:15718–15723. doi: 10.1073/pnas.95.26.15718.
    1. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Arch. Gen. Psychiatry. 2000;57:1061–1069. doi: 10.1001/archpsyc.57.11.1061.
    1. Abdolmaleky H.M., Cheng K.H., Russo A., Smith C.L., Faraone S.V., Wilcox M., Shafa R., Glatt S.J., Nguyen G., Ponte J.F., et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: A preliminary report. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005;134b:60–66. doi: 10.1002/ajmg.b.30140.
    1. Grayson D.R., Jia X., Chen Y., Sharma R.P., Mitchell C.P., Guidotti A., Costa E. Reelin promoter hypermethylation in schizophrenia. Proc. Natl. Acad. Sci. USA. 2005;102:9341–9346. doi: 10.1073/pnas.0503736102.
    1. Tochigi M., Iwamoto K., Bundo M., Komori A., Sasaki T., Kato N., Kato T. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol. Psychiatry. 2008;63:530–533. doi: 10.1016/j.biopsych.2007.07.003.
    1. Mill J., Tang T., Kaminsky Z., Khare T., Yazdanpanah S., Bouchard L., Jia P., Assadzadeh A., Flanagan J., Schumacher A., et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 2008;82:696–711. doi: 10.1016/j.ajhg.2008.01.008.
    1. Guidotti A., Grayson D.R., Caruncho H.J. Epigenetic RELN Dysfunction in Schizophrenia and Related Neuropsychiatric Disorders. Front. Cell Neurosci. 2016;10:89. doi: 10.3389/fncel.2016.00089.
    1. Mitchell A.C., Jiang Y., Peter C., Akbarian S. Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia. Schizophr. Res. 2015;167:28–34. doi: 10.1016/j.schres.2014.10.020.
    1. Guidotti A., Auta J., Chen Y., Davis J.M., Dong E., Gavin D.P., Grayson D.R., Matrisciano F., Pinna G., Satta R., et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology. 2011;60:1007–1016. doi: 10.1016/j.neuropharm.2010.10.021.
    1. Labouesse M.A., Dong E., Grayson D.R., Guidotti A., Meyer U. Maternal immune activation induces GAD1 and GAD2 promoter remodeling in the offspring prefrontal cortex. Epigenetics. 2015;10:1143–1155. doi: 10.1080/15592294.2015.1114202.
    1. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005;6:312–324. doi: 10.1038/nrn1648.
    1. Nishioka M., Bundo M., Kasai K., Iwamoto K. DNA methylation in schizophrenia: Progress and challenges of epigenetic studies. Genome Med. 2012;4:96. doi: 10.1186/gm397.
    1. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., Smith C.L., Shafa R., Aeali B., Carnevale J., et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2006;15:3132–3145. doi: 10.1093/hmg/ddl253.
    1. Iwamoto K., Bundo M., Yamada K., Takao H., Iwayama-Shigeno Y., Yoshikawa T., Kato T. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J. Neurosci. 2005;25:5376–5381. doi: 10.1523/JNEUROSCI.0766-05.2005.
    1. Rakyan V.K., Down T.A., Balding D.J., Beck S. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 2011;12:529–541. doi: 10.1038/nrg3000.
    1. Wockner L.F., Noble E.P., Lawford B.R., Young R.M., Morris C.P., Whitehall V.L., Voisey J. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl. Psychiatry. 2014;4:e339. doi: 10.1038/tp.2013.111.
    1. Nishioka M., Bundo M., Koike S., Takizawa R., Kakiuchi C., Araki T., Kasai K., Iwamoto K. Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia. J. Hum. Genet. 2013;58:91–97. doi: 10.1038/jhg.2012.140.
    1. Gavin D.P., Sharma R.P. Histone modifications, DNA methylation, and schizophrenia. Neurosci. Biobehav. Rev. 2010;34:882–888. doi: 10.1016/j.neubiorev.2009.10.010.
    1. Yap K.L., Li S., Muñoz-Cabello A.M., Raguz S., Zeng L., Mujtaba S., Gil J., Walsh M.J., Zhou M.M. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell. 2010;38:662–674. doi: 10.1016/j.molcel.2010.03.021.
    1. Lai F., Orom U.A., Cesaroni M., Beringer M., Taatjes D.J., Blobel G.A., Shiekhattar R. Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature. 2013;494:497–501. doi: 10.1038/nature11884.
    1. Schroeder F.A., Gilbert T.M., Feng N., Taillon B.D., Volkow N.D., Innis R.B., Hooker J.M., Lipska B.K. Expression of HDAC2 but Not HDAC1 Transcript Is Reduced in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia. ACS Chem. Neurosci. 2017;8:662–668. doi: 10.1021/acschemneuro.6b00372.
    1. Sharma R.P., Grayson D.R., Gavin D.P. Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: Analysis of the National Brain Databank microarray collection. Schizophr. Res. 2008;98:111–117. doi: 10.1016/j.schres.2007.09.020.
    1. Kim T., Park J.K., Kim H.J., Chung J.H., Kim J.W. Association of histone deacetylase genes with schizophrenia in Korean population. Psychiatry Res. 2010;178:266–269. doi: 10.1016/j.psychres.2009.05.007.
    1. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 2015;18:199–209. doi: 10.1038/nn.3922.
    1. Tang B., Dean B., Thomas E.A. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl. Psychiatry. 2011;1:e64. doi: 10.1038/tp.2011.61.
    1. Akbarian S., Ruehl M.G., Bliven E., Luiz L.A., Peranelli A.C., Baker S.P., Roberts R.C., Bunney W.E., Jr., Conley R.C., Jones E.G., et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry. 2005;62:829–840. doi: 10.1001/archpsyc.62.8.829.
    1. Huang H.S., Matevossian A., Whittle C., Kim S.Y., Schumacher A., Baker S.P., Akbarian S. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J. Neurosci. 2007;27:11254–11262. doi: 10.1523/JNEUROSCI.3272-07.2007.
    1. Geaghan M., Cairns M.J. MicroRNA and Posttranscriptional Dysregulation in Psychiatry. Biol. Psychiatry. 2015;78:231–239. doi: 10.1016/j.biopsych.2014.12.009.
    1. Zhang Y., Fan M., Geng G., Liu B., Huang Z., Luo H., Zhou J., Guo X., Cai W., Zhang H. A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region. Retrovirology. 2014;11:23. doi: 10.1186/1742-4690-11-23.
    1. Zhang Y., Fan M., Zhang X., Huang F., Wu K., Zhang J., Liu J., Huang Z., Luo H., Tao L., et al. Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs. RNA. 2014;20:1878–1889. doi: 10.1261/rna.045633.114.
    1. Tan H., Huang S., Zhang Z., Qian X., Sun P., Zhou X. Pan-cancer analysis on microRNA-associated gene activation. EBioMedicine. 2019;43:82–97. doi: 10.1016/j.ebiom.2019.03.082.
    1. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. USA. 2008;105:1608–1613. doi: 10.1073/pnas.0707594105.
    1. Zardo G., Ciolfi A., Vian L., Starnes L.M., Billi M., Racanicchi S., Maresca C., Fazi F., Travaglini L., Noguera N., et al. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood. 2012;119:4034–4046. doi: 10.1182/blood-2011-08-371344.
    1. Tan Y., Zhang B., Wu T., Skogerbø G., Zhu X., Guo X., He S., Chen R. Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells. BMC Mol. Biol. 2009;10:12. doi: 10.1186/1471-2199-10-12.
    1. Kim D.H., Saetrom P., Snøve O., Jr., Rossi J.J. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc. Natl. Acad. Sci. USA. 2008;105:16230–16235. doi: 10.1073/pnas.0808830105.
    1. Hwang H.W., Wentzel E.A., Mendell J.T. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315:97–100. doi: 10.1126/science.1136235.
    1. Fazi F., Rosa A., Fatica A., Gelmetti V., De Marchis M.L., Nervi C., Bozzoni I. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005;123:819–831. doi: 10.1016/j.cell.2005.09.023.
    1. Liu H., Lei C., He Q., Pan Z., Xiao D., Tao Y. Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol. Cancer. 2018;17:64. doi: 10.1186/s12943-018-0765-5.
    1. Xun Y., Tang Y., Hu L., Xiao H., Long S., Gong M., Wei C., Wei K., Xiang S. Purification and Identification of miRNA Target Sites in Genome Using DNA Affinity Precipitation. Front. Genet. 2019;10:778. doi: 10.3389/fgene.2019.00778.
    1. Xiao M., Li J., Li W., Wang Y., Wu F., Xi Y., Zhang L., Ding C., Luo H., Li Y., et al. MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol. 2017;14:1326–1334. doi: 10.1080/15476286.2015.1112487.
    1. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., Liu S., Alder H., Costinean S., Fernandez-Cymering C., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA. 2007;104:15805–15810. doi: 10.1073/pnas.0707628104.
    1. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113:6411–6418. doi: 10.1182/blood-2008-07-170589.
    1. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695–1699. doi: 10.1126/science.1165395.
    1. Duursma A.M., Kedde M., Schrier M., le Sage C., Agami R. miR-148 targets human DNMT3b protein coding region. RNA. 2008;14:872–877. doi: 10.1261/rna.972008.
    1. O’Connell R.M. MicroRNAs function on a new level. Blood. 2012;119:3875–3876. doi: 10.1182/blood-2012-02-410977.
    1. Memari F., Joneidi Z., Taheri B., Aval S.F., Roointan A., Zarghami N. Epigenetics and Epi-miRNAs: Potential markers/therapeutics in leukemia. Biomed. Pharmacother. 2018;106:1668–1677. doi: 10.1016/j.biopha.2018.07.133.
    1. Miller B.H., Zeier Z., Xi L., Lanz T.A., Deng S., Strathmann J., Willoughby D., Kenny P.J., Elsworth J.D., Lawrence M.S., et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc. Natl. Acad. Sci. USA. 2012;109:3125–3130. doi: 10.1073/pnas.1113793109.
    1. Rajman M., Schratt G. MicroRNAs in neural development: From master regulators to fine-tuners. Development. 2017;144:2310–2322. doi: 10.1242/dev.144337.
    1. Hollins S.L., Zavitsanou K., Walker F.R., Cairns M.J. Alteration of imprinted Dlk1-Dio3 miRNA cluster expression in the entorhinal cortex induced by maternal immune activation and adolescent cannabinoid exposure. Transl. Psychiatry. 2014;4:e452. doi: 10.1038/tp.2014.99.
    1. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J. Psychiatr. Res. 2005;39:311–323. doi: 10.1016/j.jpsychires.2004.08.008.
    1. Perkins D.O., Jeffries C.D., Jarskog L.F., Thomson J.M., Woods K., Newman M.A., Parker J.S., Jin J., Hammond S.M. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007;8:R27. doi: 10.1186/gb-2007-8-2-r27.
    1. Beveridge N.J., Tooney P.A., Carroll A.P., Gardiner E., Bowden N., Scott R.J., Tran N., Dedova I., Cairns M.J. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum. Mol. Genet. 2008;17:1156–1168. doi: 10.1093/hmg/ddn005.
    1. Beveridge N.J., Gardiner E., Carroll A.P., Tooney P.A., Cairns M.J. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol. Psychiatry. 2010;15:1176–1189. doi: 10.1038/mp.2009.84.
    1. Santarelli D.M., Beveridge N.J., Tooney P.A., Cairns M.J. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol. Psychiatry. 2011;69:180–187. doi: 10.1016/j.biopsych.2010.09.030.
    1. Santarelli D.M., Carroll A.P., Cairns H.M., Tooney P.A., Cairns M.J. Schizophrenia-associated MicroRNA-Gene Interactions in the Dorsolateral Prefrontal Cortex. Genom. Proteomics Bioinf. 2019;17:623–634. doi: 10.1016/j.gpb.2019.10.003.
    1. Kim A.H., Reimers M., Maher B., Williamson V., McMichael O., McClay J.L., van den Oord E.J., Riley B.P., Kendler K.S., Vladimirov V.I. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr. Res. 2010;124:183–191. doi: 10.1016/j.schres.2010.07.002.
    1. Mellios N., Galdzicka M., Ginns E., Baker S.P., Rogaev E., Xu J., Akbarian S. Gender-specific reduction of estrogen-sensitive small RNA, miR-30b, in subjects with schizophrenia. Schizophr. Bull. 2012;38:433–443. doi: 10.1093/schbul/sbq091.
    1. Wong J., Duncan C.E., Beveridge N.J., Webster M.J., Cairns M.J., Weickert C.S. Expression of NPAS3 in the human cortex and evidence of its posttranscriptional regulation by miR-17 during development, with implications for schizophrenia. Schizophr. Bull. 2013;39:396–406. doi: 10.1093/schbul/sbr177.
    1. Liu Y., Chang X., Hahn C.G., Gur R.E., Sleiman P.A.M., Hakonarson H. Non-coding RNA dysregulation in the amygdala region of schizophrenia patients contributes to the pathogenesis of the disease. Transl. Psychiatry. 2018;8:44. doi: 10.1038/s41398-017-0030-5.
    1. Lai C.Y., Yu S.L., Hsieh M.H., Chen C.H., Chen H.Y., Wen C.C., Huang Y.H., Hsiao P.C., Hsiao C.K., Liu C.M., et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS ONE. 2011;6:e21635. doi: 10.1371/journal.pone.0021635.
    1. Liu S., Zhang F., Wang X., Shugart Y.Y., Zhao Y., Li X., Liu Z., Sun N., Yang C., Zhang K., et al. Diagnostic value of blood-derived microRNAs for schizophrenia: Results of a meta-analysis and validation. Sci. Rep. 2017;7:15328. doi: 10.1038/s41598-017-15751-5.
    1. Gardiner E., Beveridge N.J., Wu J.Q., Carr V., Scott R.J., Tooney P.A., Cairns M.J. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol. Psychiatry. 2012;17:827–840. doi: 10.1038/mp.2011.78.
    1. Banigan M.G., Kao P.F., Kozubek J.A., Winslow A.R., Medina J., Costa J., Schmitt A., Schneider A., Cabral H., Cagsal-Getkin O., et al. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS ONE. 2013;8:e48814. doi: 10.1371/journal.pone.0048814.
    1. Shi W., Du J., Qi Y., Liang G., Wang T., Li S., Xie S., Zeshan B., Xiao Z. Aberrant expression of serum miRNAs in schizophrenia. J. Psychiatr. Res. 2012;46:198–204. doi: 10.1016/j.jpsychires.2011.09.010.
    1. Wei H., Yuan Y., Liu S., Wang C., Yang F., Lu Z., Wang C., Deng H., Zhao J., Shen Y., et al. Detection of circulating miRNA levels in schizophrenia. Am. J. Psychiatry. 2015;172:1141–1147. doi: 10.1176/appi.ajp.2015.14030273.
    1. Ma J., Shang S., Wang J., Zhang T., Nie F., Song X., Heping Z., Zhu C., Zhang R., Hao D. Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia. Psychiatry Res. 2018;265:70–76. doi: 10.1016/j.psychres.2018.03.080.
    1. Geaghan M.P., Atkins J.R., Brichta A.M., Tooney P.A., Scott R.J., Carr V.J., Cairns M.J. Alteration of miRNA-mRNA interactions in lymphocytes of individuals with schizophrenia. J. Psychiatr. Res. 2019;112:89–98. doi: 10.1016/j.jpsychires.2019.02.023.
    1. Zhao Z., Jinde S., Koike S., Tada M., Satomura Y., Yoshikawa A., Nishimura Y., Takizawa R., Kinoshita A., Sakakibara E., et al. Altered expression of microRNA-223 in the plasma of patients with first-episode schizophrenia and its possible relation to neuronal migration-related genes. Transl. Psychiatry. 2019;9:289. doi: 10.1038/s41398-019-0609-0.
    1. Du Y., Yu Y., Hu Y., Li X.W., Wei Z.X., Pan R.Y., Li X.S., Zheng G.E., Qin X.Y., Liu Q.S., et al. Genome-Wide, Integrative Analysis Implicates Exosome-Derived MicroRNA Dysregulation in Schizophrenia. Schizophr. Bull. 2019;45:1257–1266. doi: 10.1093/schbul/sby191.
    1. Yu H.C., Wu J., Zhang H.X., Zhang G.L., Sui J., Tong W.W., Zhang X.Y., Nie L.L., Duan J.H., Zhang L.R., et al. Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2015;63:23–29. doi: 10.1016/j.pnpbp.2015.05.007.
    1. Derrien T., Johnson R., Bussotti G., Tanzer A., Djebali S., Tilgner H., Guernec G., Martin D., Merkel A., Knowles D.G., et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–1789. doi: 10.1101/gr.132159.111.
    1. Barry G. Integrating the roles of long and small non-coding RNA in brain function and disease. Mol. Psychiatry. 2014;19:410–416. doi: 10.1038/mp.2013.196.
    1. Faghihi M.A., Zhang M., Huang J., Modarresi F., Van der Brug M.P., Nalls M.A., Cookson M.R., St-Laurent G., 3rd, Wahlestedt C. Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol. 2010;11:R56. doi: 10.1186/gb-2010-11-5-r56.
    1. Wang Y., Xu Z., Jiang J., Xu C., Kang J., Xiao L., Wu M., Xiong J., Guo X., Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev. Cell. 2013;25:69–80. doi: 10.1016/j.devcel.2013.03.002.
    1. Leucci E., Patella F., Waage J., Holmstrøm K., Lindow M., Porse B., Kauppinen S., Lund A.H. microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci. Rep. 2013;3:2535. doi: 10.1038/srep02535.
    1. Mercer T.R., Mattick J.S. Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 2013;20:300–307. doi: 10.1038/nsmb.2480.
    1. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., Shi Y., Segal E., Chang H.Y. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689–693. doi: 10.1126/science.1192002.
    1. Khalil A.M., Guttman M., Huarte M., Garber M., Raj A., Rivea Morales D., Thomas K., Presser A., Bernstein B.E., van Oudenaarden A., et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. USA. 2009;106:11667–11672. doi: 10.1073/pnas.0904715106.
    1. Ng S.Y., Johnson R., Stanton L.W. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. Embo J. 2012;31:522–533. doi: 10.1038/emboj.2011.459.
    1. Ng S.Y., Bogu G.K., Soh B.S., Stanton L.W. The long noncoding RNA RMST interacts with SOX2 to regulate neurogenesis. Mol. Cell. 2013;51:349–359. doi: 10.1016/j.molcel.2013.07.017.
    1. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., Devon R.S., St Clair D.M., Muir W.J., Blackwood D.H., et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 2000;9:1415–1423. doi: 10.1093/hmg/9.9.1415.
    1. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., Millar J.K. The DISC locus in psychiatric illness. Mol. Psychiatry. 2008;13:36–64. doi: 10.1038/sj.mp.4002106.
    1. Barry G., Briggs J.A., Vanichkina D.P., Poth E.M., Beveridge N.J., Ratnu V.S., Nayler S.P., Nones K., Hu J., Bredy T.W., et al. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing. Mol. Psychiatry. 2014;19:486–494. doi: 10.1038/mp.2013.45.
    1. Rao S.Q., Hu H.L., Ye N., Shen Y., Xu Q. Genetic variants in long non-coding RNA MIAT contribute to risk of paranoid schizophrenia in a Chinese Han population. Schizophr. Res. 2015;166:125–130. doi: 10.1016/j.schres.2015.04.032.
    1. Spadaro P.A., Flavell C.R., Widagdo J., Ratnu V.S., Troup M., Ragan C., Mattick J.S., Bredy T.W. Long Noncoding RNA-Directed Epigenetic Regulation of Gene Expression Is Associated With Anxiety-like Behavior in Mice. Biol. Psychiatry. 2015;78:848–859. doi: 10.1016/j.biopsych.2015.02.004.
    1. Hu J., Xu J., Pang L., Zhao H., Li F., Deng Y., Liu L., Lan Y., Zhang X., Zhao T., et al. Systematically characterizing dysfunctional long intergenic non-coding RNAs in multiple brain regions of major psychosis. Oncotarget. 2016;7:71087–71098. doi: 10.18632/oncotarget.12122.
    1. Mahmoudi E., Fitzsimmons C., Geaghan M.P., Shannon Weickert C., Atkins J.R., Wang X., Cairns M.J. Circular RNA biogenesis is decreased in postmortem cortical gray matter in schizophrenia and may alter the bioavailability of associated miRNA. Neuropsychopharmacology. 2019;44:1043–1054. doi: 10.1038/s41386-019-0348-1.
    1. Karlsson O., Baccarelli A.A. Environmental Health and Long Non-coding RNAs. Curr. Environ. Health Rep. 2016;3:178–187. doi: 10.1007/s40572-016-0092-1.
    1. Sullivan P.F., Fan C., Perou C.M. Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006;141b:261–268. doi: 10.1002/ajmg.b.30272.
    1. Murphy B.C., O’Reilly R.L., Singh S.M. Site-specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005;133b:37–42. doi: 10.1002/ajmg.b.30134.
    1. Hess J.L., Tylee D.S., Barve R., de Jong S., Ophoff R.A., Kumarasinghe N., Tooney P., Schall U., Gardiner E., Beveridge N.J., et al. Transcriptome-wide mega-analyses reveal joint dysregulation of immunologic genes and transcription regulators in brain and blood in schizophrenia. Schizophr. Res. 2016;176:114–124. doi: 10.1016/j.schres.2016.07.006.
    1. Auta J., Smith R.C., Dong E., Tueting P., Sershen H., Boules S., Lajtha A., Davis J., Guidotti A. DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. Schizophr. Res. 2013;150:312–318. doi: 10.1016/j.schres.2013.07.030.
    1. Aberg K.A., Xie L.Y., McClay J.L., Nerella S., Vunck S., Snider S., Beardsley P.M., van den Oord E.J. Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions. Epigenomics. 2013;5:367–377. doi: 10.2217/epi.13.36.
    1. Aberg K.A., McClay J.L., Nerella S., Clark S., Kumar G., Chen W., Khachane A.N., Xie L., Hudson A., Gao G., et al. Methylome-wide association study of schizophrenia: Identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71:255–264. doi: 10.1001/jamapsychiatry.2013.3730.
    1. Walton E., Hass J., Liu J., Roffman J.L., Bernardoni F., Roessner V., Kirsch M., Schackert G., Calhoun V., Ehrlich S. Correspondence of DNA Methylation Between Blood and Brain Tissue and Its Application to Schizophrenia Research. Schizophr. Bull. 2016;42:406–414. doi: 10.1093/schbul/sbv074.
    1. Braun P.R., Han S., Hing B., Nagahama Y., Gaul L.N., Heinzman J.T., Grossbach A.J., Close L., Dlouhy B.J., Howard M.A., 3rd, et al. Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. Transl. Psychiatry. 2019;9:47. doi: 10.1038/s41398-019-0376-y.
    1. Melas P.A., Rogdaki M., Ösby U., Schalling M., Lavebratt C., Ekström T.J. Epigenetic aberrations in leukocytes of patients with schizophrenia: Association of global DNA methylation with antipsychotic drug treatment and disease onset. Faseb J. 2012;26:2712–2718. doi: 10.1096/fj.11-202069.
    1. Gao S., Cheng J., Li G., Sun T., Xu Y., Wang Y., Du X., Xu G., Duan S. Catechol-O-methyltransferase gene promoter methylation as a peripheral biomarker in male schizophrenia. Eur. Psychiatry. 2017;44:39–46. doi: 10.1016/j.eurpsy.2017.03.002.
    1. Nohesara S., Ghadirivasfi M., Mostafavi S., Eskandari M.R., Ahmadkhaniha H., Thiagalingam S., Abdolmaleky H.M. DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J. Psychiatr. Res. 2011;45:1432–1438. doi: 10.1016/j.jpsychires.2011.06.013.
    1. Kordi-Tamandani D.M., Dahmardeh N., Torkamanzehi A. Evaluation of hypermethylation and expression pattern of GMR2, GMR5, GMR8, and GRIA3 in patients with schizophrenia. Gene. 2013;515:163–166. doi: 10.1016/j.gene.2012.10.075.
    1. Ikegame T., Bundo M., Sunaga F., Asai T., Nishimura F., Yoshikawa A., Kawamura Y., Hibino H., Tochigi M., Kakiuchi C., et al. DNA methylation analysis of BDNF gene promoters in peripheral blood cells of schizophrenia patients. Neurosci. Res. 2013;77:208–214. doi: 10.1016/j.neures.2013.08.004.
    1. Carrard A., Salzmann A., Malafosse A., Karege F. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. J. Affect. Disord. 2011;132:450–453. doi: 10.1016/j.jad.2011.03.018.
    1. Ghadirivasfi M., Nohesara S., Ahmadkhaniha H.R., Eskandari M.R., Mostafavi S., Thiagalingam S., Abdolmaleky H.M. Hypomethylation of the serotonin receptor type-2A Gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011;156b:536–545. doi: 10.1002/ajmg.b.31192.
    1. Abdolmaleky H.M., Yaqubi S., Papageorgis P., Lambert A.W., Ozturk S., Sivaraman V., Thiagalingam S. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr. Res. 2011;129:183–190. doi: 10.1016/j.schres.2011.04.007.
    1. Ikegame T., Bundo M., Murata Y., Kasai K., Kato T., Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J. Hum. Genet. 2013;58:434–438. doi: 10.1038/jhg.2013.65.
    1. Bromberg A., Levine J., Nemetz B., Belmaker R.H., Agam G. No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr. Res. 2008;101:50–57. doi: 10.1016/j.schres.2008.01.009.
    1. Bönsch D., Wunschel M., Lenz B., Janssen G., Weisbrod M., Sauer H. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Res. 2012;198:533–537. doi: 10.1016/j.psychres.2011.09.004.
    1. Murata Y., Ikegame T., Koike S., Saito T., Ikeda M., Sasaki T., Iwata N., Kasai K., Bundo M., Iwamoto K. Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2020;99:109855. doi: 10.1016/j.pnpbp.2019.109855.
    1. Starnawska A., Demontis D., McQuillin A., O’Brien N.L., Staunstrup N.H., Mors O., Nielsen A.L., Børglum A.D., Nyegaard M. Hypomethylation of FAM63B in bipolar disorder patients. Clin. Epigenetics. 2016;8:52. doi: 10.1186/s13148-016-0221-6.
    1. Hannon E., Dempster E., Viana J., Burrage J., Smith A.R., Macdonald R., St Clair D., Mustard C., Breen G., Therman S., et al. An integrated genetic-epigenetic analysis of schizophrenia: Evidence for co-localization of genetic associations and differential DNA methylation. Genome Biol. 2016;17:176. doi: 10.1186/s13059-016-1041-x.
    1. Arion D., Corradi J.P., Tang S., Datta D., Boothe F., He A., Cacace A.M., Zaczek R., Albright C.F., Tseng G., et al. Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. Mol. Psychiatry. 2015;20:1397–1405. doi: 10.1038/mp.2014.171.
    1. Watkeys O.J., Cohen-Woods S., Quidé Y., Cairns M.J., Overs B., Fullerton J.M., Green M.J. Derivation of poly-methylomic profile scores for schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2020;101:109925. doi: 10.1016/j.pnpbp.2020.109925.
    1. Kano S., Colantuoni C., Han F., Zhou Z., Yuan Q., Wilson A., Takayanagi Y., Lee Y., Rapoport J., Eaton W., et al. Genome-wide profiling of multiple histone methylations in olfactory cells: Further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol. Psychiatry. 2013;18:740–742. doi: 10.1038/mp.2012.120.
    1. Kuzman M.R., Medved V., Terzic J., Krainc D. Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. J. Psychiatr. Res. 2009;43:1073–1077. doi: 10.1016/j.jpsychires.2009.03.005.
    1. Cascella N.G., Takaki M., Lin S., Sawa A. Neurodevelopmental involvement in schizophrenia: The olfactory epithelium as an alternative model for research. J. Neurochem. 2007;102:587–594. doi: 10.1111/j.1471-4159.2007.04628.x.
    1. Horiuchi Y., Kano S., Ishizuka K., Cascella N.G., Ishii S., Talbot C.C., Jr., Jaffe A.E., Okano H., Pevsner J., Colantuoni C., et al. Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: Utility and limitation of the surrogate tissues in research for brain disorders. Neurosci. Res. 2013;77:247–250. doi: 10.1016/j.neures.2013.09.010.
    1. Borgmann-Winter K., Willard S.L., Sinclair D., Mirza N., Turetsky B., Berretta S., Hahn C.G. Translational potential of olfactory mucosa for the study of neuropsychiatric illness. Transl. Psychiatry. 2015;5:e527. doi: 10.1038/tp.2014.141.
    1. Liu S., Zhang F., Shugart Y.Y., Yang L., Li X., Liu Z., Sun N., Yang C., Guo X., Shi J., et al. The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. Transl. Psychiatry. 2017;7:e998. doi: 10.1038/tp.2016.268.
    1. Pérez-Santiago J., Diez-Alarcia R., Callado L.F., Zhang J.X., Chana G., White C.H., Glatt S.J., Tsuang M.T., Everall I.P., Meana J.J., et al. A combined analysis of microarray gene expression studies of the human prefrontal cortex identifies genes implicated in schizophrenia. J. Psychiatr. Res. 2012;46:1464–1474. doi: 10.1016/j.jpsychires.2012.08.005.
    1. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA. 2008;105:10513–10518. doi: 10.1073/pnas.0804549105.
    1. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006. doi: 10.1038/cr.2008.282.
    1. Zen K., Zhang C.Y. Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 2012;32:326–348. doi: 10.1002/med.20215.
    1. Liang H., Gong F., Zhang S., Zhang C.Y., Zen K., Chen X. The origin, function, and diagnostic potential of extracellular microRNAs in human body fluids. Wiley Interdiscip Rev. RNA. 2014;5:285–300. doi: 10.1002/wrna.1208.
    1. Burmistrova O.A., Goltsov A.Y., Abramova L.I., Kaleda V.G., Orlova V.A., Rogaev E.I. MicroRNA in schizophrenia: Genetic and expression analysis of miR-130b (22q11) Biochemistry. 2007;72:578–582. doi: 10.1134/S0006297907050161.
    1. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., Tait J.F., Tewari M. Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev. Res. 2012;5:492–497. doi: 10.1158/1940-6207.CAPR-11-0370.
    1. Sheinerman K.S., Umansky S.R. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front. Cell Neurosci. 2013;7:150. doi: 10.3389/fncel.2013.00150.
    1. Ren Y., Cui Y., Li X., Wang B., Na L., Shi J., Wang L., Qiu L., Zhang K., Liu G., et al. A co-expression network analysis reveals lncRNA abnormalities in peripheral blood in early-onset schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2015;63:1–5. doi: 10.1016/j.pnpbp.2015.05.002.
    1. Chen S., Sun X., Niu W., Kong L., He M., Li W., Zhong A., Lu J., Zhang L. Aberrant Expression of Long Non-Coding RNAs in Schizophrenia Patients. Med. Sci. Monit. 2016;22:3340–3351. doi: 10.12659/MSM.896927.
    1. Sun X.Y., Zhang J., Niu W., Guo W., Song H.T., Li H.Y., Fan H.M., Zhao L., Zhong A.F., Dai Y.H., et al. A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2015;168b:170–178. doi: 10.1002/ajmg.b.32292.
    1. Alacam H., Akgun S., Akca H., Ozturk O., Kabukcu B.B., Herken H. miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia. Psychiatry Res. 2016;245:200–206. doi: 10.1016/j.psychres.2016.08.037.
    1. Alfimova M.V., Kondratiev N.V., Golov A.K., Golimbet V.E. [Methylation of the Reelin Gene Promoter in Peripheral Blood and Its Relationship with the Cognitive Function of Schizophrenia Patients] Mol. Biol. 2018;52:782–792. doi: 10.1134/S0026893318050023.
    1. Wu S., Zhang R., Nie F., Wang X., Jiang C., Liu M., Valenzuela R.K., Liu W., Shi Y., Ma J. MicroRNA-137 Inhibits EFNB2 Expression Affected by a Genetic Variant and Is Expressed Aberrantly in Peripheral Blood of Schizophrenia Patients. EBioMedicine. 2016;12:133–142. doi: 10.1016/j.ebiom.2016.09.012.
    1. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002;12:735–739. doi: 10.1016/S0960-9822(02)00809-6.
    1. Mahmoudi E., Cairns M.J. MiR-137: An important player in neural development and neoplastic transformation. Mol. Psychiatry. 2017;22:44–55. doi: 10.1038/mp.2016.150.
    1. Guella I., Sequeira A., Rollins B., Morgan L., Torri F., van Erp T.G., Myers R.M., Barchas J.D., Schatzberg A.F., Watson S.J., et al. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J. Psychiatr. Res. 2013;47:1215–1221. doi: 10.1016/j.jpsychires.2013.05.021.
    1. Green M.J., Cairns M.J., Wu J., Dragovic M., Jablensky A., Tooney P.A., Scott R.J., Carr V.J. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol. Psychiatry. 2013;18:774–780. doi: 10.1038/mp.2012.84.
    1. Peedicayil J. Identification of Biomarkers in Neuropsychiatric Disorders Based on Systems Biology and Epigenetics. Front. Genet. 2019;10:985. doi: 10.3389/fgene.2019.00985.
    1. Carvalho A.F., Solmi M., Sanches M., Machado M.O., Stubbs B., Ajnakina O., Sherman C., Sun Y.R., Liu C.S., Brunoni A.R., et al. Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Transl. Psychiatry. 2020;10:152. doi: 10.1038/s41398-020-0835-5.
    1. Fernandes B.S., Steiner J., Bernstein H.G., Dodd S., Pasco J.A., Dean O.M., Nardin P., Gonçalves C.A., Berk M. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: Meta-analysis and implications. Mol. Psychiatry. 2016;21:554–564. doi: 10.1038/mp.2015.87.
    1. Winship I.R., Dursun S.M., Baker G.B., Balista P.A., Kandratavicius L., Maia-de-Oliveira J.P., Hallak J., Howland J.G. An Overview of Animal Models Related to Schizophrenia. Can. J. Psychiatry. 2019;64:5–17. doi: 10.1177/0706743718773728.
    1. Kundakovic M., Gudsnuk K., Herbstman J.B., Tang D., Perera F.P., Champagne F.A. DNA methylation of BDNF as a biomarker of early-life adversity. Proc. Natl. Acad. Sci. USA. 2015;112:6807–6813. doi: 10.1073/pnas.1408355111.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel